Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin
The DOI matches its Crossref record.
Abstract
We report the treatment of four patients with inclusion-body myositis (IBM) and severe slowly progressive weakness using high-dose intravenous immunoglobulin (IVIg). After two monthly infusions, the strength of the proximal and less atrophic muscle groups improved or normalized in three of the four patients. The improvement lasted from 2 to 4 months. Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy. In view of the high cost of IVIg, the unexpected but encouraging results from this pilot study warrant a controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Self-citationInclusion body myositis and myopathies
Griggs, R. C., Askanas, V., DiMauro, S., Engel, A., Karpati, G., Mendell, J. R., & Rowland, L. P. (1995) · Annals of Neurology · doi:10.1002/ana.410380504 · Cited by 837
Inclusion body myositis: clinical features and pathogenesis
Greenberg, S. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0186-x · Cited by 273
Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches
Needham, M., & Mastaglia, F. L. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70171-0 · Cited by 269
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Metadata
- Authors
- Soueidan, S. A., & Dalakas, M. C.
- Venue
- Neurology
- Published
- 1993-05
- Volume
- 43
- Issue
- 5
- Pages
- 876-876
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2004520740
- Cited by
- 130
- References
- 0
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin. https://app.cochat.ai/papers/10.1212/wnl.43.5.876
- The paper
- Soueidan, S. A., & Dalakas, M. C. (1993). Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin. Neurology. https://doi.org/10.1212/wnl.43.5.876
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.